![John Shiver](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Shiver
Direktor/Vorstandsmitglied bei
NOVAVAX, INC.
Vermögen: 87 179 $ am 31.05.2026
Profil
John W.
Shiver is currently Director at International AIDS Vaccine Initiative, Inc. since 2018, Independent Director at Novavax, Inc. starting in 2025, Director at Calder Biosciences, Inc., Director at AuraVax Therapeutics, Inc., and Special Advisor at F-Prime, Inc. since 2022.
Former positions include President & Director at Sanofi Pasteur VaxDesign Corp., Independent Director at Icosavax, Inc. from 2022 to 2024, Vice President-Vaccine & Biologics Basic Research at Merck & Co., Inc., and Chief Strategy Officer-Infectious Diseases Unit at IGM Biosciences, Inc. from 2021 to 2023.
Education includes a doctorate from the University of Florida conferred in 1985 and an undergraduate degree from Wofford College conferred in 1978.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 23.04.2026 | 7 947 ( 0 % ) | 87 179 $ | 31.05.2026 |
Aktive Positionen von John Shiver
| Unternehmen | Position | Beginn |
|---|---|---|
| NOVAVAX, INC. | Direktor/Vorstandsmitglied | 10.03.2025 |
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops vaccines for AIDS | Direktor/Vorstandsmitglied | 01.09.2018 |
Impresa Management LLC
 Impresa Management LLC Investment ManagersFinance F-Prime invests in companies located in Asia, Europe, North America, and South America. The firm focuses on companies operating in the life sciences, technology, healthtech services, and crypto sectors. It provides financing for seed, early, and later stage capital requirements. | Berater | 01.11.2022 |
AURAVAX THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
Calder Biosciences, Inc.
 Calder Biosciences, Inc. BiotechnologyHealth Technology Develops vaccine immunogens | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von John Shiver
| Unternehmen | Position | Ende |
|---|---|---|
| ICOSAVAX, INC. | Direktor/Vorstandsmitglied | 19.02.2024 |
| IGM BIOSCIENCES, INC. | Corporate Officer/Principal | 01.12.2023 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Sanofi Pasteur VaxDesign Corp.
 Sanofi Pasteur VaxDesign Corp. Miscellaneous Commercial ServicesCommercial Services Develops, manufactures, & markets in vitro models of human immune systems | Präsident | - |
Ausbildung von John Shiver
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
80
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Novavax, Inc.
 Novavax, Inc. BiotechnologyHealth Technology Engages in development of novel recombinant vaccines | Health Technology |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops vaccines for AIDS | Health Technology |
University of Florida
 University of Florida Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wofford College
 Wofford College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi Pasteur VaxDesign Corp.
Sanofi Pasteur VaxDesign Corp. Miscellaneous Commercial ServicesCommercial Services Develops, manufactures, & markets in vitro models of human immune systems | Commercial Services |
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance F-Prime invests in companies located in Asia, Europe, North America, and South America. The firm focuses on companies operating in the life sciences, technology, healthtech services, and crypto sectors. It provides financing for seed, early, and later stage capital requirements. | Finance |
IGM Biosciences, Inc.
 IGM Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered IgM antibodies for the treatment of cancer patients | Health Technology |
Icosavax, Inc.
 Icosavax, Inc. BiotechnologyHealth Technology Develops vaccines for infectious disease | Health Technology |
Calder Biosciences, Inc.
Calder Biosciences, Inc. BiotechnologyHealth Technology Develops vaccine immunogens | Health Technology |
AURAVAX THERAPEUTICS, INC. |
